A biosensing platform for
decentralized healthcare.

Nanostic Technologies develops connected biosensing systems that bring clinical-grade measurement to the patient — extending the reach of healthcare beyond traditional clinical settings, where care meets the people it's meant to serve.

Explore the platform For investors & partners
Founded Copenhagen, Denmark · 2024
Quality System ISO 13485 in development
Stage Active R&D · Pre-clinical · Pilot 2027
The shift

Healthcare is moving closer to the patient.

Care is extending into environments that traditional medical infrastructure was never designed for.

The most meaningful clinical decisions are increasingly being made outside the hospital — in the patient's daily life, in their recovery, in the long quiet stretches between visits. The infrastructure that enables clinical-grade insight in those moments is what we build.

Decentralized. Connected. Clinical-grade.

The platform

Built for clinical-grade reliability.

A connected biosensing system designed end-to-end — engineered with healthcare providers, validated through clinical engagement, and built to operate in the environments where modern care is moving.

Progress

Built with hospitals, not just for them.

Clinical engagement leads our development. Active dialogue with hospital departments across Europe. Letters of Intent from clinical partners. A 14-partner Horizon Europe consortium, conceived and organized by Nanostic. National innovation programs as financial backbone.

40+
Clinician interviews across European hospitals
7
Signed Letters of Intent from clinical partners
14
Partners in Horizon Europe — REMODEL consortium
€130k+
Soft funding secured
— Programs, institutions & consortia
★ Horizon Europe — REMODEL Consortium ★ Entrepreneurship World Cup 2024 · Top 100 Global Rigshospitalet Technical University of Denmark Innovationsfonden InnoBooster InnoFounder DTU Science Park DTU MedTech Growth DTU Skylab Beyond Accelerate Global Entrepreneurship Network
★ Horizon Europe · Application submitted

A 14-partner consortium conceived and organized by Nanostic Technologies.

REMODEL — submitted to Horizon Europe under the DISEASE-03 call, advancing research on the prevention, diagnosis, and management of post-infection long-term conditions. A multi-disciplinary consortium spanning clinical, technical, regulatory, and health-economic expertise.

14 partners 8 European countries Call: HORIZON-HLTH-2026-01-DISEASE-03
Application submitted under Horizon Europe — Research and Innovation programme. Evaluation outcome expected Q4 2026.
The team

Clinical, scientific, and engineering depth — assembled deliberately.

— Leadership
Filip Angelov
Founder · CEO & CTO

Filip Angelov

Founder · CEO & CTO

Biomedical engineering · Immunology · Tech-transfer

Dr. Gunhild Lange Skovgaard
Co-Founder · CMO

Dr. Gunhild Lange Skovgaard

Co-Founder · Chief Medical Officer

Professor of Medicine · Former Center Director, Rigshospitalet

Søren Skovlund
Co-Founder · CPO

Søren Skovlund

Co-Founder · Chief Product Officer

Hardware product design & development · 20+ years

— Team
— ENG
Muhtasim Meya

Microelectronics & Digital Architecture

— OPS
Marc Cervantes

Soft-Funding Coordinator

— OPS
Khaled Waleed

Project Management & Operations

— LAB
Nikodem Galazka

Student Assistant

— R&D
Mahdi Al Wakiel

R&D Intern

— Board
Claus Hansen
Board · Finance & Governance

Claus Hansen

Finance & Governance

Novo Holdings · Finance leadership

Hans Flemming Jensen
Board · Fundraising & Strategy

Hans Flemming Jensen

Fundraising & Strategy

Nilfisk · Senior operator · M&A and venture scaling

— Get in touch

For investors, healthcare providers, and strategic partners.

Detailed materials — investor deck, technical brief, regulatory roadmap, and clinical engagement summary — are available upon request.

office@nanosticstech.com LinkedIn
office@nanosticstech.com · Copenhagen, Denmark